First Mercantile Trust’s Esperion Therapeutics ESPR Stock Holding History

First Mercantile Trust’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,771	Closed	-$345K	–	933
2018 Q1	$345K	Buy	4,771 +538	+13%	+$39.5K	0.07%	331
2017 Q4	$279K	Buy	4,233 +1,519	+56%	+$81.8K	0.05%	431
2017 Q3	$136K	Buy	+2,714	New	+$131K	0.02%	648
2016 Q2	–	Sell	-10,054	Closed	-$170K	–	888
2016 Q1	$170K	Sell	10,054 -1,468	-13%	-$23.6K	0.02%	614
2015 Q4	$256K	Buy	11,522 +2,167	+23%	+$54.7K	0.03%	606
2015 Q3	$221K	Buy	9,355 +1,900	+25%	+$119K	0.02%	638
2015 Q2	$610K	Buy	7,455 +2,200	+42%	+$215K	0.05%	440
2015 Q1	$487K	Buy	+5,255	New	+$339K	0.04%	505

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return

PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return